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Abstract
Background—Adults are recommended to receive select vaccinations based on their age, 
underlying medical conditions, lifestyle, and other considerations. Factors associated with 
awareness of vaccine-preventable diseases and recommended vaccines among adults in the United 
States have not been explored.
Methods—Data from a 2015 internet panel survey of a nationally representative sample of U.S. 
adults aged ≥19 years were analyzed to assess awareness of selected vaccine-preventable diseases 
and recommended vaccines for adults. A multivariable logistic regression model with a predictive 
marginal approach was used to identify factors independently associated with awareness of 
selected vaccine-preventable infections/diseases and corresponding vaccines.
Results—Among the surveyed population, from 24.6 to 72.1% reported vaccination for 
recommended vaccines. Awareness of vaccine-preventable diseases among adults aged ≥19 years 
ranged from 63.4% to 94.0% (63.4% reported awareness of HPV, 71.5% reported awareness of 
tetanus, 72.0% reported awareness of pertussis, 75.4% reported awareness of HZ, 75.8% reported 
awareness of hepatitis B, 83.1% reported awareness of pneumonia, and 94.0% reported awareness 
of influenza). Awareness of the corresponding vaccines among adults aged ≥19 years ranged from 
59.3% to 94.1% (59.3% HZ vaccine, 59.6% HPV vaccine, 64.3% hepatitis B vaccine, 66.2% 
pneumococcal vaccine, 86.3% tetanus vaccines, and 94.1% influenza vaccine). In multivariable 
analysis, being female and being a college graduate were significantly associated with a higher 
level of awareness for majority of vaccine-preventable diseases, and being female, being a college 
graduate, and working as a health care provider were significantly associated with a higher level of 
awareness for majority of corresponding vaccines.
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Conclusions—Although adults in this survey reported high levels of awareness for most 
vaccines recommended for adults, self-reported vaccination coverage was not optimal. Combining 
interventions known to increase uptake of recommended vaccines, such as patient reminder/recall 
systems and other health-care system-based interventions, and ensuring patients’ vaccination 
needs are assessed, are needed to improve vaccination of adults.
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1. Introduction
The prevalence of vaccine-preventable diseases is higher among adults than among children 
[1–4]. Every year thousands of adults in the United States suffer serious health problems, are 
hospitalized, and die due to diseases for which vaccines are available [5]. During the 2015–
16 season, influenza hospitalization rates ranged from 20.3 per 100,000 to 321.1 per 
100,000, depending on age group, with an estimated 310,000 hospitalizations [2]. About 
74% of these hospitalizations occurred among adults aged 50 years and older [2]. 
Approximately 28,000 cases of invasive pneumococcal disease occur annually, of which 
90% are among adults [5,6]. Human papillomavirus (HPV) is the most common sexually 
transmitted infection in the United States. More than 50% of sexually active men and 
women will acquire HPV infection in their lifetime [7], and an estimated 6.2 million persons 
aged 14–44 years are newly infected every year [8,9]. Of these new infections, 74% occur 
among persons age 15–24 years [8]. Approximately 1 million cases of herpes zoster (HZ, 
shingles) are reported annually among older adults in the United States, with approximately 
10–50% of those affected suffering post-herpetic neuralgia [4,10,11].
Vaccination is the most effective strategy for preventing vaccine-preventable diseases and 
their complications. The adult immunization schedule [12], updated annually by the 
Advisory Committee on Immunization Practices (ACIP), provides current recommendations 
for vaccinating adults. However, adult vaccination coverage remains low for most routinely 
recommended vaccines and is well below Healthy People 2020 targets [13–15]. Low 
vaccination coverage might be related to low awareness of both vaccine-preventable diseases 
and recommended vaccines for adults [13]. Data on awareness among adults in the United 
States of vaccine-preventable diseases and recommended vaccines are limited [16].
We used data from a 2015 internet panel survey of a nationally representative sample of U.S. 
adults aged ≥19 years to assess their awareness of selected vaccine-preventable diseases and 
vaccines including influenza, pneumococcal (including both polysaccharide and conjugate 
vaccines), tetanus (tetanus-diphtheria toxoid [Td] and tetanus diphtheria with acellular 
pertussis [Tdap]), HPV, and herpes zoster, and their self-reported vaccination status. We 
evaluated factors independently associated with awareness of selected vaccine-preventable 
diseases and vaccines among adult populations.
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2. Methods
An Internet panel survey of U.S. adults was conducted in early 2015 for the Centers for 
Diseases Control and Prevention (CDC) by Abt Associates, Inc. (Cambridge, 
Massachusetts). Survey participants were recruited from KnowledgePanel®, a pre-existing 
national probability-based internet panel operated by Gesellschaft für Konsumforschung 
(GfK) [17]. A nationally representative sample of U.S. adults ≥19 years of age was selected; 
Hispanics, non-Hispanic blacks, and non-Hispanic other adults or adults identifying multiple 
races were oversampled. The survey field period was February 27 to March 23, 2015. 
Overall, 4016 notification emails were sent to sampled panel members, 2760 were 
confirmed contacts (defined as touching the opening page of the survey either as a click-
through from the email link provided by GfK or directly from the KnowledgePanel® 
member portal), and 2683 completed the survey, with a response rate of 67%, and 
cooperation rate of 97%. Estimates were weighted to the adult population of the United 
States.
The survey collected information about the National Vaccine Advisory Committee Standards 
for Adult Immunization Practice [18], including adult experience of vaccination assessment, 
recommendation, offer, and referral during healthcare and/or pharmacy visits in the past 12 
months. The survey also collected other vaccination-related information, including adult 
vaccination, knowledge of vaccine-preventable diseases and vaccines.
We examined awareness of selected vaccine-preventable diseases and vaccines by selected 
covariates. Persons with health conditions that increase the risk for pneumococcal infections 
were defined as persons who currently have one or more of the following conditions: chronic 
lung condition (i.e., asthma, chronic bronchitis, chronic obstructive pulmonary disease, 
emphysema), any kind of liver condition, weak or failing kidneys, a chronic heart condition 
(i.e., coronary heart disease, angina, heart attack, or other heart disease), diabetes other than 
gestational diabetes, and a weakened immune system. To determine travel status, 
respondents were asked “Have you ever traveled outside of the United States to countries 
other than Europe, Japan, Australia, New Zealand or Canada, since 1995?” For the purposes 
of this study we referred to travelers to hepatitis B-endemic areas as “travelers”.
We used SAS release 9.3 (SAS Inc. Cary, NC) and SUDAAN 11.0 (RTI, Research Triangle 
Park, NC) to analyze the data. All analyses were weighted to reflect the U.S. adult 
population. T-tests were used to test for differences in vaccination coverage and awareness 
of selected vaccine-preventable diseases and vaccines by the selected covariates. A two-
sided significance level of 0.05 was adopted for all statistical tests. A multivariable logistic 
regression model with a predictive marginal approach was used to identify factors 
independently associated with awareness of selected vaccine-preventable diseases and 
vaccines among adult populations.
3. Results
Characteristics of the study population are shown in Table 1. In our study population, 5.5% 
of participants reported that cost was a barrier to receiving vaccines in the past 12 months, 
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and 5.2% reported that they were unable to receive a vaccine in the past 12 months because 
their insurance did not cover the cost.
Among all adults aged ≥19 years, 50.0% reported influenza vaccination; influenza 
vaccination was significantly higher among those aged 50–64 years (50.3%) and aged ≥65 
years (74.7%) compared with those aged 19–49 years (41.3%) (Table 2). In adults aged 19–
64 years with conditions that increase the risk for pneumococcal disease, 37.5% reported 
pneumococcal vaccination compared with 72.1% of adults aged ≥65 years. For adults aged 
≥19 years, 67.9% reported tetanus vaccination with a greater proportion of those aged 50–64 
years (72.2%) and those aged ≥65 years (81.4%) reporting vaccination compared with adults 
aged 19–49 years (61.0%). Among adults aged ≥19 years, 24.6% reported hepatitis B 
vaccination. Of adults ≥60 years, 35.2% reported herpes zoster vaccination. HPV 
vaccination was reported by 27.1% of females aged 19–26 years (Table 2).
Overall awareness of vaccine-preventable diseases and vaccines was high for most 
demographic groups. Among all adults aged ≥19 years, awareness of vaccine-preventable 
diseases ranged from 63.4% (HPV) to 94.0% (influenza) (Table 3). Awareness among adults 
of the corresponding vaccines against these diseases was similar to or higher than awareness 
of the disease for influenza, HPV, and Td/Tdap vaccines; vaccine awareness was lower than 
disease awareness for pneumococcal, hepatitis B, and HZ vaccines (Table 4).
Table 3 also presents the results of bi-variable analyses to assess characteristics associated 
with higher or lower level of awareness of selected vaccine-preventable diseases. Being a 
college graduate, and having a high-risk condition were significantly associated with a 
higher level of awareness of all the vaccine-preventable diseases assessed among adults aged 
≥19 years. Being female, and having private health insurance were significantly associated 
with a higher level of awareness for 6 of 7 of the vaccine-preventable diseases assessed. 
Being in an older age group was significantly associated with a higher level of awareness for 
all of the diseases assessed except hepatitis B and HPV. Hispanic ethnicity was significantly 
associated with a lower level of awareness of all the vaccine-preventable diseases assessed. 
Report of being “never married” was significantly associated with a lower level of awareness 
of all the vaccine-preventable diseases assessed except hepatitis B, HZ, and HPV.
Table 4 shows the results of bi-variable analyses to assess characteristics associated with 
level of awareness of selected vaccines. Being female, having a high-risk condition, living in 
a household with an income of $25,000–$74,999, living in a household with an income ≥
$75,000, and having private health insurance were significantly associated with a higher 
level of awareness for 5 of the 6 vaccines assessed among adults aged ≥19 years. Being a 
college graduate was significantly associated with a higher level of awareness for all of the 
vaccines assessed except influenza and pneumococcal vaccines. Being in an older age group 
was significantly associated with a higher level of awareness for all of the vaccines assessed 
except Td/Tdap and HPV. Non-Hispanic black race/ethnicity was significantly associated 
with a lower level of awareness for all of the vaccines assessed except hepatitis B. Hispanic 
ethnicity was significantly associated with a lower level of awareness for all the vaccines 
assessed except HPV. Report of being “never married” was significantly associated with a 
lower level of awareness of all of the vaccines assessed except Hepatitis B and HPV.
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Table 5 shows the results of multivariable analyses to assess characteristics independently 
associated with higher or lower level of awareness of selected vaccine-preventable diseases. 
Being female was significantly associated with a higher level of awareness for all of the 
vaccine-preventable diseases assessed among adults aged ≥19 years except influenza. Being 
a college graduate was significantly associated with a higher level of awareness for all of the 
vaccine-preventable diseases assessed among adults aged ≥19 years except pneumonia and 
HZ disease. Hispanic ethnicity was significantly associated with a lower level of awareness 
for tetanus, pertussis, HZ, and HPV disease.
Table 6 shows the results of multivariable analyses to assess characteristics associated with 
higher or lower level of awareness of selected vaccines. Being female and being a college 
graduate were significantly associated with a higher level of awareness for all vaccines 
assessed among adults aged ≥19 years except influenza and pneumococcal vaccines. 
Volunteering or working in a healthcare setting was associated with a higher awareness of all 
vaccines assessed except influenza and Td/Tdap vaccines. Being in an older age group was 
significantly associated with a higher level of awareness for all vaccines except influenza, 
hepatitis B, and Td/Tdap. Non-Hispanic black race/ethnicity was significantly associated 
with a lower level of awareness for all vaccines except influenza, pneumococcal, and 
hepatitis B vaccines.
4. Discussion
Overall, adult vaccination coverage was low, especially among younger adults. Awareness of 
selected vaccine-preventable diseases among adults aged ≥19 years ranged from a high of 
94.0% (influenza) to a low of 63.4% (HPV, though awareness was 66.8% for adults aged 
19–26 years), and awareness of vaccines ranged from 94.1% (influenza) to 59.3% (HZ, 
though awareness was 73.4% for adults aged ≥60 years). The characteristics that were 
associated with awareness of selected vaccine-preventable diseases and vaccines varied by 
diseases and vaccines. To our knowledge, this is the first comprehensive assessment of 
awareness of selected vaccine-preventable diseases and vaccines recommended for adults. 
This study provides baseline data for monitoring of U.S. adults’ awareness of selected 
vaccine-preventable diseases and vaccines.
The percentages of persons vaccinated with adult vaccines in this report is similar to that 
from other national studies, especially for HZ and HPV vaccination [13,14,19]. Several 
studies have demonstrated persistent racial/ethnic differences in receipt of routinely 
recommended adult vaccines [13,14,19]. Previous studies also found that having health 
insurance coverage and a usual place for health care are each associated with higher 
vaccination coverage among adults [13,20–22]. Characteristics that might contribute to low 
vaccination coverage among adult populations might include limited public awareness about 
adult vaccinations, lack of vaccine requirements for adults, lack of provider assessment, 
recommendation, and referral of routine vaccinations for adults during health care visits, the 
cost of stocking vaccines, inadequate and/or inconsistent payment for vaccines and vaccine 
administration, complexities in adult vaccine and administration payment by private as well 
as public insurers, and lack of health insurance and limited funding for programs to 
vaccinate uninsured adults [13,20–29].
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While cost is often cited as a potential barrier to receiving vaccines, this study found only 
5.5% of respondents reported that cost was a barrier to receiving vaccines in the past 12 
months, and 5.2% of participants reported that they were unable to receive a vaccine in the 
past 12 months because their insurance did not cover the cost. This was a small portion of 
the population and indicated that cost was not as big a barrier as we think for adult 
populations. The Patient Protection and Affordable Care Act requires that certain clinical 
preventive services including all ACIP recommended vaccines be provided at no cost by 
qualified health plans and with no or limited cost-sharing under Medicare. These policy 
changes should help to improve adult vaccination coverage [30,31].
Furthermore, in our study, awareness was generally high for most vaccine-preventable 
diseases and vaccines. Awareness for some vaccine-preventable diseases and vaccines were 
particularly high. For example, awareness of both influenza disease and influenza vaccine 
was as high as 94%. High awareness but low vaccination coverage seen in the study might 
indicate that high awareness does not always result in high vaccination coverage, and 
awareness was not enough to motivate individuals to get vaccinated [32]. Further study is 
needed to understand the role of awareness on vaccination seeking and vaccination accepting 
behavior. Possible reasons for higher awareness of influenza disease and vaccine include the 
prevalence of influenza and the high rates of influenza-related morbidity and mortality 
among adults in the United States, the seasonality of influenza compared to other diseases 
that do not have seasonal peaks, media attention that is usually pervasive during influenza 
seasons, and influenza vaccination promotion activities and events organized by national and 
local organizations [1,13,33–35].
Overall, lower awareness for some vaccine-preventable diseases and vaccines could be a 
consequence of providers not recommending vaccination to their adult patients. More 
physician contacts may indicate more opportunities to discuss their health status and 
vaccination indications with their providers and thus patients may know or understand more 
about diseases and vaccinations. Failure to seek out routine and preventive medical care 
might be related to low awareness of some vaccine-preventable diseases and recommended 
vaccines. For example, about 26% of adults under 50 years did not see a provider in the past 
12 months (CDC unpublished data). Individuals who did not see a provider in the past 12 
months had lower vaccination coverage with the exception of hepatitis B and HPV vaccines 
based on our study. Awareness of the need for vaccinations might increase the frequency of 
provider visits. Low awareness might lead to possibly lower chance of accepting vaccination 
if offered. Since patients may not seek vaccination services, each provider visit, including 
non-routine visits, is a critical opportunity to ensure provider implementation of vaccination 
services, assessing vaccination needs and recommending necessary adult vaccines to protect 
adult patients and improve coverage.
Adult awareness of both HZ and HPV vaccines for vaccination recommended groups 
(73.4% among those ≥60 years, and 65.8% among those 19–26 years, respectively) was 
overall lower than awareness of influenza vaccine (94.1% among those ≥19 years). This 
lower awareness might be due to the relatively more recent national recommendations for 
these vaccines (first recommended for adults in 2006–2007) compared with influenza 
vaccine and that influenza vaccination is promoted and offered annually, providing many 
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opportunities to increase awareness [8,36]. Awareness of HZ vaccine based on our study has 
increased compared with the 2007 estimate (27%), however awareness of HPV vaccine 
decreased compared with the 2007 estimate (76–83%) [37,38]. Efforts should be directed to 
provide comprehensive, accessible, and appropriate communication messages on HPV 
vaccine [8]. Patients aged ≥60 years must also be fully educated on the potential risks and 
benefits of the HZ vaccine and vaccine payment options. Improved awareness about shingles 
vaccine could improve vaccination coverage and further reduce incidence of shingles and its 
associated complications.
Several racial and ethnic differences in awareness of vaccine-preventable diseases and 
vaccines were noted: adults of non-Hispanic black and Hispanic race/ethnicity had 
significantly lower awareness for most diseases and vaccines compared with adults of non-
Hispanic white race/ethnicity. Some studies have demonstrated lower disease and vaccine-
related knowledge levels among adults of non-Hispanic black and Hispanic race/ethnicity 
compared with adults of non-Hispanic white race/ethnicity [37–41]. This finding might 
reflect lower prevalence of vaccination services being offered to black and Hispanic patients, 
and lower knowledge levels can limit the ability of patients to request vaccination when 
appropriate [37–41]. Female respondents had a higher level of awareness of most of the 
diseases and vaccines than men. This finding remained after controlling for other factors. 
Consistent with other studies, higher education level was also associated with higher 
awareness of most diseases and vaccines [37–41]. These results suggest that efforts should 
be made to provide better education about diseases and vaccines to non-Hispanic black, 
Hispanic, and other race/ethnicity adults, adult males, and adults with lower levels of 
education.
The findings from this study showed that working or volunteering in a health care setting 
was associated with higher level of awareness of many vaccines compared with not working 
or volunteering in this setting. Additionally, up to one third of respondents who reported 
working or volunteering in health care did not indicate awareness of select vaccines (3% 
reported not being aware of influenza vaccine, 10% Td/Tdap, 23% HPV, 30% 
pneumococcal, 33% hepatitis B, and 34% shingles). Individuals who work or volunteer in 
health care settings can acquire infectious diseases from patients or transmit infectious 
diseases to patients, visitors, other staff, and their own families [42,43]. By 2014, influenza, 
Tdap, and hepatitis B vaccination coverage among health care personnel were not optimal 
(65.4%, 42.1%, and 60.7%, respectively) [13]. Employer vaccination requirements or on on-
site vaccination services were important to improve vaccination coverage and reduce 
transmission of infectious disease in health care settings [29,42].
The findings in this study are subject to limitations. First, data for this study were collected 
by self-report. Vaccination was not verified by medical records and may be subject to recall 
bias. However, adult self-reported vaccination status has been shown to be sensitive and 
specific [44–47]. Second, non-coverage and nonresponse bias may remain even after 
weighting adjustments. Finally, those who respond to internet surveys or agree to be on 
internet survey panels may not be representative of the US adult population.
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The findings from this study demonstrate previously reported low vaccination coverage 
among U.S. adults, but relatively high levels of awareness. Further research is needed to 
understand the role of awareness of vaccine-preventable diseases and vaccines [48] and ways 
to reduce the gap between awareness and vaccination. The Standards for Adult 
Immunization Practice should be incorporated into routine clinical practice for every visit 
regardless of clinical setting [18]. Combining interventions known to increase uptake of 
recommended vaccines, such as patient reminder/recall systems and healthcare system-based 
interventions (e.g., client reminder and recall systems, clinic-based client education, 
expanded access in health care settings, provider assessment and feedback, provider 
reminders, and use of standing order programs), and ensuring patients’ vaccination needs are 
assessed, are needed to improve vaccination of adults [18,29].
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Table 1
Demographic, health, health care employment, and health care access characteristics of adults aged ≥19 years 
participating in an Internet panel survey, on vaccination assessment and recommendations by providers at 
healthcare visits, United States, February–March 2015.
Characteristic
All adults
Sample (N) Weighteda %
Total 2683 100.0
Age
 19–49 years 1198 54.9
 50–64 years 767 26.3
 ≥65 years 718 18.8
Sex
 Male 1282 48.2
 Female 1401 51.8
Race/ethnicity
 Hispanic 636 15.1
 Non-Hispanic white 793 65.6
 Non-Hispanic black 613 11.5
 Other 641 7.8
Marital status
 Married or unmarried couple 1602 60.4
 Divorced, widowed, or separated 516 16.7
 Never married 565 22.9
Education level
 ≤high school 992 40.7
 Some college or technical school 544 22.0
 College graduate or higher education 1147 37.4
Employment
 Employed 1411 56.1
 Unemployed 203 8.1
 Not in work force 1069 35.8
Annual household income
 <$25,000 561 20.1
 $25,000–$74,999 1127 38.9
 ≥$75,000 995 40.9
Region
 Northeast 437 17.8
 Midwest 474 21.6
 South 1028 37.2
 West 744 23.4
Metropolitan Statistical Area
 Yes 2369 85.1
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Characteristic
All adults
Sample (N) Weighteda %
 No 314 14.9
Conditions that increase risk for pneumococcal diseasea
 Yes 823 30.0
 No 1685 70.0
Health-care personnelb
 Yes 198 6.6
 No 2473 93.4
Health insurance
 Private 1729 67.2
 Public only 757 25.3
 None 186 7.5
Provider visit for health care in the past 12 months
 Yes 2297 95.1
 No 120 4.9
Unable to receive vaccine due to cost in the past 12 months
 Yes 152 5.5
 No 2428 94.5
Unable to receive vaccine because insurance did not cover in the past 12 months
 Yes 139 5.2
 No 2413 94.8
Living with a child <18 years
 Yes 788 32.6
 No 1895 67.4
aCurrently have one or more chronic medical conditions (a doctor, nurse, or other medical professional ever said that you have at least one of the 
following): lung or breathing problem (e.g., asthma or other chronic lung problem), any kind of liver condition, any kind of kidney condition, or 
any kind of heart condition (other than high blood pressure), diabetes or sugar diabetes (other than during pregnancy); and respond that still have 
that condition/those conditions), or currently have weakened immune system (a doctor, nurse, or other medical professional ever said that you have 
a weakened immune system, and still have that condition).
bVolunteered or worked in a hospital, medical clinic, doctor’s office, dentist’s office, nursing home, pharmacy, or some other health-care facility in 
the past 12 months.
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Table 2
Vaccination reported by adults aged ≥19 years participating in a panel survey on vaccination assessment and 
recommendations by providers at healthcare visits, by demographic, health and travel characteristics, 
February–March 2015.
Vaccinations and age groups Vaccination coverage % (95% CI)
Influenza vaccination (last 12 months)
 ≥19 years 50.0 (47.3–52.6)
 19–49 years 41.3 (37.6–45.0)
 50–64 years 50.3 (45.6–55.0)a
 ≥65 years 74.7 (69.0–79.6)a
Pneumococcal vaccination (ever received)
 19–64 years with conditions that increase risk for pneumococcal diseaseb 37.5 (31.1–44.4)
 ≥65 years 72.1 (66.1–77.4)a
Tetanus vaccination (ever received)
 ≥19 years 67.9 (65.3–70.5)
 19–49 years 61.0 (57.1–64.8)
 50–64 years 72.2 (67.9–76.1)a
 ≥65 years 81.4 (76.1–85.7)a
Hepatitis B vaccination (ever received)
 ≥19 years 24.6 (22.2–27.2)
 19–49 years 27.6 (24.2–31.3)
 ≥50 years 20.9 (17.7–24.4)a
 Travelers to hepatitis B-endemic areas aged ≥19 years 34.8 (30.3–39.6)
 Non-travelers to hepatitis B-endemic areas aged ≥19 years 19.5 (16.8–22.5)a
Shingles vaccination (ever received)
 ≥60 years 35.2 (30.2–40.6)
 60–64 years 25.2 (18.0–34.2)
 ≥65 years 40.1 (33.7–46.9)a
Human papillomavirus vaccination (ever received)
 Male aged 19–26 years
–
c
 Female aged 19–26 years 27.1 (18.2–38.4)
ap < 0.05 by T test comparing against reference group (50–64 and 65+ vs. 19–49; 65+ vs 19–64 HR; 50+ vs 19–49; 19+ travelers vs 19+ non-
travelers; 65+ vs 60–64).
bCurrently have one or more chronic medical conditions (a doctor, nurse, or other medical professional ever said that you have at least one of the 
following): lung or breathing problem (e.g., asthma or other chronic lung problem), any kind of liver condition, any kind of kidney condition, or 
any kind of heart condition (other than high blood pressure), diabetes or sugar diabetes (other than during pregnancy); and respond that still have 
that condition/those conditions), or currently have weakened immune system (a doctor, nurse, or other medical professional ever said that you have 
a weakened immune system, and still have that condition).
c
Estimate may not be reliable due to relative standard error (RSE) > 30%.
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